Featured Story | By Nick Paul Taylor Merck has struck a $1.9 billion deal to buy Pandion. The takeover will give Merck control of a pipeline of immune modulators led by a rival to IL-2 drugs in development at Amgen, Eli Lilly and Roche. read more |
| |
|---|
|
Top Stories By Ben Adams As Moderna ramps up its COVID-19 vaccine efforts and has made one of the speediest moves from a hyped-up preclinical biotech to a commercial entity hoping to help save the world, its chief medical officer, Tal Zaks, M.D., Ph.D., is set to leave for pastures new. read more By Nick Paul Taylor A phase 2 clinical trial of GlaxoSmithKline’s otilimab in hospitalized COVID-19 patients has missed its primary endpoint. However, a preplanned analysis of older patients found signs of efficacy, leading GSK to expand the cohort in a bid to validate the finding. read more In Partnership With: AmerisourceBergen The Canadian pharmaceutical market, which is among the 10 largest worldwide, has long been viewed as a top-tier launch destination. read more By Amirah Al Idrus Jaguar Gene Therapy comes out of stealth with a team of AveXis alumni, series A funding from Deerfield and access to the VC shop’s network of 18 academic institutions for potential future programs. It starts out with four preclinical-stage gene therapies, one of which is being developed at its subsidiary, Axovia Therapeutics. read more By Amirah Al Idrus New approach to drug design, check. New CEO, check. Now, Cellarity is raising $123 million in venture capital to propel multiple programs targeting cell behavior toward the clinic and keep improving the technology that underlies those assets. read more By Conor Hale With its eyes set on securing an FDA clearance for its automated bench top blood testing system, Truvian Sciences has gathered more than $105 million in new financing and added inventor Dean Kamen, former Livongo CEO Glen Tullman and Abbott's Jay Srinivasan to its team. read more By Angus Liu Scientists continue to search for vaccines and drugs to add to the anti-COVID-19 arsenal. Now two research groups have announced discoveries related to the changing structure of the SARS-CoV-2 coronavirus that caused the pandemic, and they believe their insights could aid in the development of new weapons to fight the virus. read more By Eric Sagonowsky Moderna, racing to produce as many COVID-19 vaccine doses as possible this year, says it expects to reap $18.4 billion from its shot this year. read more Enrollment Showcase | Sponsored by: University of Florida College of Pharmacy Learn about the Top 5-Ranked UF College of Pharmacy’s online graduate programs in pharmaceutical outcomes & policy. Select from five specializations, including the new pharmaceutical value assessment & communication option. Over half of graduates progress to a new role within one year. Register now. |
| |
|---|
|
Resources Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored By: Medidata, a Dassault Systèmes company 8 parameters to optimize your “Path to Virtualization” across site- and patient-centric capabilities in this Sponsor Edition eBook. Sponsored By: LabVantage Solutions Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored By: Acorn AI, a Medidata Company Acorn AI has developed a flexible and scalable Commercial Data Model that provides pharmaceutical companies with the data-driven insights required to respond to the industry’s ever-changing landscape. Download the whitepaper to learn how Acorn AI’s intuitive data model enables launch success and more. Sponsored By: Outer Edge Technology Criminals Are Actively Exploiting The CV-19 Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become A Cybercrime Statistic -- Make These Cost-Effective IT Changes Now! Sponsored by: Cytiva It’s an exciting time to pioneer what could be a life-changing medicine. Clear the path to the clinic with pro tips and expert insights from industry leaders. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Premier Research Browse the latest learnings and insights from our clinical development professionals. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
